NCT07424963 Hepatic Venous Pressure Gradient Versus Endoscopic Ultrasound-Guided Portal Pressure Gradient - Comparative Analysis (HEPCA)
| NCT ID | NCT07424963 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Military University Hospital, Prague |
| Condition | Cirrhosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-05-30 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-05-30 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this interventional trial is to compare in measuring of portal hypertension by HVPG and EUS-PPG in subject indicated to HVPG measurement. The primary question is whether EUS-PPG provides measurements really equivalent to HVPG in terms of gradient accuracy. Participants undergoing HVPG will first undergo the procedure while conscious, performed by the first operator. Immediately thereafter, HVPG will be repeated following the induction of anesthesia by a second operator blinded to the initial readings. Subsequently, EUS-PPG will be performed by an endoscopist, who will also be blinded to all previous pressure measurements.
Eligibility Criteria
Inclusion Criteria: * Age 18-75 years at the time of enrollment; signed informed consent * Clinical indication for HVPG measurement and/or transjugular liver biopsy for chronic advanced liver disease Exclusion Criteria: * Severe co-morbidities (e.g., advanced chronic heart failure, chronic renal insufficiency stage 4 and above, long-term poorly compensated diabetes mellitus with severe complications) * Pregnancy * Estimated patient non-compliance and/or not signing of the informed consent * Documented iodine contrast dye allergy * Presence of portal vein thrombosis or cavernomatous transformation of portal vein or hepatic vein obstruction * Ascites Grade 3 * Biliary obstruction * Anticoagulation or antiplatelet therapy, which cannot be discontinued * INR \> 1.5 and/or platelet count \< 50,000/µl * Hepatocellular carcinoma in the left lobe of the liver * Surgically altered upper gastrointestinal tract anatomy * State after transjugular intrahepatic portosystemic shunt * State after liver transplantation
Contact & Investigator
Petr Hříbek, MD, PhD
PRINCIPAL INVESTIGATOR
Military University Hospital, Prague
Frequently Asked Questions
Who can join the NCT07424963 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Cirrhosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07424963 currently recruiting?
Yes, NCT07424963 is actively recruiting participants. Contact the research team at petr.hribek@uvn.cz for enrollment information.
Where is the NCT07424963 trial being conducted?
This trial is being conducted at Prague, Czechia, Prague, Czechia.
Who is sponsoring the NCT07424963 clinical trial?
NCT07424963 is sponsored by Military University Hospital, Prague. The principal investigator is Petr Hříbek, MD, PhD at Military University Hospital, Prague. The trial plans to enroll 40 participants.